Legal & General Group’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-7,277
| Closed | -$38K | – | 3504 |
|
|
2019
Q2 | $38K | Hold |
7,277
| – | – | ﹤0.01% | 2908 |
|
|
2019
Q1 | $26K | Hold |
7,277
| – | – | ﹤0.01% | 3003 |
|
|
2018
Q4 | $45K | Buy |
7,277
+1,053
| +17% | +$6.43K | ﹤0.01% | 2739 |
|
|
2018
Q3 | $36K | Hold |
6,224
| – | – | ﹤0.01% | 2944 |
|
|
2018
Q2 | $26K | Sell |
6,224
-1,949
| -24% | -$9.83K | ﹤0.01% | 3089 |
|
|
2018
Q1 | $36K | Sell |
8,173
-3,208
| -28% | -$14.3K | ﹤0.01% | 2908 |
|
|
2017
Q4 | $60K | Sell |
11,381
-5
| -0% | -$31 | ﹤0.01% | 2813 |
|
|
2017
Q3 | $70K | Hold |
11,386
| – | – | ﹤0.01% | 2806 |
|
|
2017
Q2 | $82K | Buy |
11,386
+1,654
| +17% | +$10.2K | ﹤0.01% | 2708 |
|
|
2017
Q1 | $52K | Sell |
9,732
-193
| -2% | -$1.3K | ﹤0.01% | 2859 |
|
|
2016
Q4 | $72K | Buy |
9,925
+4,543
| +84% | +$36.7K | ﹤0.01% | 2742 |
|
|
2016
Q3 | $48K | Hold |
5,382
| – | – | ﹤0.01% | 2543 |
|
|
2016
Q2 | $34K | Hold |
5,382
| – | – | ﹤0.01% | 2671 |
|
|
2016
Q1 | $29K | Hold |
5,382
| – | – | ﹤0.01% | 2596 |
|
|
2015
Q4 | $31K | Hold |
5,382
| – | – | ﹤0.01% | 2631 |
|
|
2015
Q3 | $44K | Hold |
5,382
| – | – | ﹤0.01% | 2518 |
|
|
2015
Q2 | $80K | Hold |
5,382
| – | – | ﹤0.01% | 2284 |
|
|
2015
Q1 | $89K | Buy |
5,382
+1,310
| +32% | +$23.3K | ﹤0.01% | 2126 |
|
|
2014
Q4 | $72K | Hold |
4,072
| – | – | ﹤0.01% | 2222 |
|
|
2014
Q3 | $43K | Buy |
+4,072
| New | +$49.4K | ﹤0.01% | 2472 |
|
Other funds holding PETX
Legal & General Group's PETX Position: Q3 2019 in Review
Legal & General Group sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 7,277 shares — an estimated $38K sold.
Legal & General Group first reported a position in PETX in Q3 2014 and held it in 20 quarters. The position peaked at $89K in Q1 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Legal & General Group reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Legal & General Group sold 7,277 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $38K.
- Legal & General Group first reported a position in Aratana Therapeutics, Inc. in Q3 2014 and held it in 20 quarters.
- Legal & General Group's Aratana Therapeutics, Inc. position peaked at $89K in Q1 2015.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Legal & General Group's 13F filing for Q3 2019, filed 13 Nov 2019.